Study of SYH2062 Injection in Healthy Chinese Volunteers
Phase 1
Recruiting
- Conditions
- Healthy Chinese Volunteers
- Interventions
- Drug: SYH2062 injectionDrug: SYH2062-Matching placebo
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-04-30
- Target Recruit Count
- 46
- Registration Number
- NCT06842537
- Locations
- 🇨🇳
Chinese Academy of Medical Science and Peking Union Medical College Hospital, Beijing, Beijing, China
Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting
Phase 3
Not yet recruiting
- Conditions
- Post-operative Nausea and Vomiting (PONV)
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 486
- Registration Number
- NCT06543966
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2053
- First Posted Date
- 2024-01-29
- Last Posted Date
- 2025-04-04
- Target Recruit Count
- 39
- Registration Number
- NCT06229548
- Locations
- 🇨🇳
10 Chedaogou Rd.,Haidian District, Beijing, China, Beijing, Beijing, China
A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia
Phase 3
Not yet recruiting
- Conditions
- High-risk (Secondary) Acute Myeloid Leukemia
- Interventions
- Drug: Liposomal cytarabine-daunorubicin for injectionDrug: 7+3 (cytarabine and daunorubicin)
- First Posted Date
- 2023-12-27
- Last Posted Date
- 2023-12-28
- Target Recruit Count
- 120
- Registration Number
- NCT06182592
- Locations
- 🇨🇳
Institute of Hematology and Hospital of Blood Disease, Chinese Academy of Medical Sciences, Tianjin, China
Bioequivalence of Amphotericin B Liposome for Injection
Phase 1
Completed
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-09-28
- Target Recruit Count
- 32
- Registration Number
- NCT05913921
- Locations
- 🇨🇳
Haikou people's Hospital, Haikou, Hainan, China
A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection
- First Posted Date
- 2023-04-06
- Last Posted Date
- 2023-09-21
- Target Recruit Count
- 36
- Registration Number
- NCT05801835
- Locations
- 🇨🇳
Institute of Hematology and Hospital of Blood Disease, Chinese Academy of Medical Sciences, Tianjin, China
A Study of Clevidipine Butyrate Injectable Emulsion in the Treatment of Hypertensive Emergency and Sub-emergency
Phase 3
Not yet recruiting
- Conditions
- Hypertensive Emergency
- Interventions
- First Posted Date
- 2023-03-24
- Last Posted Date
- 2023-03-24
- Target Recruit Count
- 398
- Registration Number
- NCT05783557
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment
Phase 3
Not yet recruiting
- Conditions
- Recurrent Metastatic Nasopharyngeal Carcinoma
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2023-02-08
- Target Recruit Count
- 500
- Registration Number
- NCT05717764
Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
Phase 2
Completed
- Conditions
- Neuromyelitis Optica Spectrum Disorder
- Interventions
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2024-08-07
- Target Recruit Count
- 46
- Registration Number
- NCT05551598
- Locations
- 🇨🇳
Xuanwu Hospital Capital Medical University, Beijing, Beijing, China
A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis
Phase 2
Withdrawn
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Locations
- 🇨🇳
Xuanwu Hospital Capital Medical University, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath